Patents
Method of enhancing neural stem cell proliferation, differentiation, and survival using pituitary adenylate cyclase activating polypeptide (PACAP)
Patent Number: 7,368,115Pharmaceutical activation of stem cells is arguably the next major revolution in medicine. The current patent is assigned to a Canadian stem cell company, Stem Cell Therapeutics (TSX-V:SSS), which already has entered Phase II clinical trials with pharmaceutical activators of endogenous stem cells for the treatment of stroke. While the ongoing clinical work of Stem Cell Therapeutics involves...
Inventors: Ohta; Shigeki (Tokyo, JP), Weiss; Samuel (Calgary, CA)
Assignee: Stem Cell Therapeutics Inc. (Calgary, Alberta, Canada)
Date of First Priority Issue: Wednesday July 31st, 2002
Multi-lineage directed induction of bone marrow stromal cell differentiation
Patent Number: 7,364,900This patent covers a 2 step method of generating insulin producing cells. According to the first issued claim, the initial step involves obtaining what essentially appears to be a mesenchymal stem cell (adherent cell positive for CD44, CD90 and CD71, negative for monocyte and hematopoietic markers, CD11b and CD45, respectively) and culturing them with an antioxidant in order to generate an...
Inventors: Black; Ira B. (Skillman, NJ), Woodbury; Dale (Middletown, NJ)
Assignee: University of Medicine and Dentistry of New Jersey (Somerset, NJ)
Date of First Priority Issue: Wednesday September 5th, 2001
Loop peptide and TGF.alpha. for stimulating stem cell proliferation and migration
Patent Number: 7,365,172Stem cells need to be maintained in a quiescent state when they are not needed to make new cells. This is because if stem cells were consistently proliferating then there would be a high propability of mutations, thus leading to cancer. One of the methods that stem cells maintain themselves in a non-proliferating state is through autocrine secretion of inhibitory factors. One...
Inventors: Twardzik; Daniel R (Bainbridge Island, WA), Paskell; Stefan (Bainbridge Island, WA), Felker; Thomas S (Vashon, WA)
Assignee: Applied Protein Sciences LLC (Mountain View, CA)
Date of First Priority Issue: Monday April 26th, 1999
Methods of cancer therapy targeted against a cancer stem line
Patent Number: 7,361,336The concept of the cancer stem cell revolves around the notion that 99% of cells making a tumor mass, while deadly, are not the ones that keep the tumor growing. The <1% of cells of a tumor, which possess unique surface markers and functional activities are the ones that continually cause the tumor to keep growing. According to this idea, drug development in cancer for the past 50...
Inventors: Bergstein; Ivan
Assignee: Stemline
Date of First Priority Issue: Tuesday September 16th, 1997
Multipotent neural stem cell compositions
Patent Number: 7,361,505Essentially, this patent covers: a) fetal and embryonic derived neurospheres; b) purified population of multipotent neural derived from juvenile or adult mammalian CNS tissue; and c) in vitro cell culture composition derived from mammalian CNS consisting of neurospheres.Specific neurospheres include cells that resemble neuronal progenitor cells. The phenotype of these...
Inventors: Weiss; Samuel (Calgary, CA), Reynolds; Brent (Alberta, CA)
Assignee: Neurospheres Holdings Ltd. (Alberta, CA)
Date of First Priority Issue: Monday July 8th, 1991
Differentiation of specialized dermal and epidermal cells into neuronal cells
Patent Number: 7,361,506This patent covers ways of manufacturing cells that express dopaminergic neurons for implantation. Obviously one of the uses for these cells is treatment of Parkinson's. While others have generated dopaminergic neurons from sources such as subventricular zone precursors, olfactory epithelium, and
Assignee: Creative Science Solutions, Inc. (Richmond, VA)
Date of First Priority Issue: Wednesday April 18th, 2001
Placental growth factor as a target for the treatment of osteoporosis
Patent Number: 7,357,929This patent covers the inhibition of placental growth factor as a method of treating osteoporosis. The one issued claim is restricted to inhibition of placental growth factor using an antibody or fragments of the antibody.The inventor demonstrated inhibition of bone resorption in an animal model, as well as in vitro using anti-placental growth factor antibodies. Interestingly in the...
Inventors: Carmeliet; Peter (Blanden, BE), Collen; Desire (Winksele, BE), Bouillon; Roger (Winksele, BE), Carmeliet; Gertrudis (Blanden, BE)
Assignee: D. Collen Research Foundation VZW (Leuven, BE)
Date of First Priority Issue: Friday June 28th, 2002
1 Comment
1 Comment
Device and method for culturing cells
Patent Number: 7,358,082This patent covers a method of culturing cells, including stem cells by providing flow conditions simular to what may be found in an in vivo system. The invention aims to meet the following goals: (1) supplying a substance uniformly to the cells to be cultured; (2) establishing a uniform flow for supplying a substance; (3) eliminating a dead space; and (4) preventing release of cell layers...
Inventors: Tsuzuki; Hirohiko (Kanagawa, JP), Toda; Satoru (Kanagawa, JP), Ichikawa; Yasunori (Kanagawa, JP), Kurahashi; Tetsuo (Kanagawa, JP), Shiraishi; Fumiko (Kanagawa, JP)
Assignee: FUJIFILM Corporation (Tokyo, JP)
Date of First Priority Issue: Wednesday July 16th, 2003
Method for rapid generation of mature dendritic cells
Patent Number: 7,354,909Dendritic cells are the most potent stimulators of the immune system. Generally it is the dendritic cell that picks up antigens and makes the decision whether the immune system should "get mad" and go after the antigen, or whether the antigen represents no substantial danger and therefore should be ignored. In some cases the dendritic...
Inventors: Klinman; Dennis M. (Potomac, MD), Gursel; Mayda (Ankara, TR), Verthelyi; Daniela (Potomac, MD)
Assignee: The United States of America as represented by Secretary of the Department of Health and Human Services (Washington, DC)
Date of First Priority Issue: Tuesday August 14th, 2001
Generating vascular smooth muscle cells in vitro from ES cells
Patent Number: 7,354,763This patent covers the generation of vascular smooth muscle cells from embryonic stem cells through specific culture conditions. In one embodiment the differentiation is induced through exposure to the cytokines TGF, angiopoietin, and platelet derived growth factor BB. In the examples section the generation of SMA positive cells from embryonic stem cells is demonstrated, as well as...
Inventors: Gerecht-Nir; Sharon (Haifa, IL), Itskovitz-Eldor; Joseph (Haifa, IL)
Assignee: Technion Research & Development Foundation Ltd. (Haifa, IL)
Date of First Priority Issue: Friday April 5th, 2002